Result of a collaboration between the CNRS, the VRI, Montpellier University, Inserm, the Institut Pasteur, the Henri-Mondor AP-HP hospital in Créteil, and the Gui de Chauliac hospital (CHU de Montpellier), French researchers have identified a marker that makes it possible to differentiate “dormant” HIV-infected cells from healthy cells. This discovery will make it possible to isolate and analyze reservoir cells which, by silently hosting the virus, are responsible for its persistence even among patients receiving antiviral treatment, whose viral load is undetectable. It offers new therapeutic strategies for targeting infected cells. This research is published in the journal Nature on March 15, 2017.
Today, the International AIDS Society (IAS) announced the plenary speakers and programme for the 9th IAS Conference on HIV Science (IAS 2017). Hosted in partnership with ANRS (The French National Agency for Research on AIDS and Viral Hepatitis), the conference will take place from 23-26 July 2017 in Paris, France.
The plenary program will feature sessions that cover innovative prevention, treatment, and care approaches for HIV. The speakers will spotlight the latest developments in vaccines, cure research for hepatitis B, cancer and immune-based therapies, as well as providing new insights into improved preventative and therapeutic measures.
Yves Lévy (Inserm) will speak about “Harnessing the Immune System to Prevent and Control HIV Infection” on Monday 24th of July 2017
Two candidate vaccines targeting dendritic cells have been developed at the Vaccine Research Institute (VRI), and their manufacture under cGMP guidelines will permit the set-up of future clinical trials in humans.
The 21st International AIDS Conference took place from July 17 2016 to July 22 2016 in Durban, South Africa http://www.aids2016.org/
The ANRS attended the 21st Conference of the IAS and hosted a satellite symposium "Oral PrEP on demand: an alternative to daily PrEP?" . PrEP was at the heart of the next IAS conference in Durban, where the most recent results of international studies have been discussed.
The ANRS took part in presenting the final results of the Ipergay trial (open phase) and hosting a satellite symposium on PrEP on demand. Preclinical studies in animal models, clinical trials and pharmacokinetic studies in favor of the strategy "on demand" and the WHO guidelines were presented and discussed.
The symposium was introduced by Ms. Marisol Touraine, Minister of Social Affairs and Health.
UN Secretary-General Mr Ban Ki-moon announced the creation of a “Global Health Crises” Task Force, which will bring together 3 co-leads and 12 members, including Inserm Chairman and CEO Yves Lévy.
The Task Force will ensure the implementation and monitoring of the recommendations of the report, “Protecting humanity from future health crises,” submitted to the UN Secretary-General in February 2016 by the High-level Panel on the Global Response to Health Crises.
The main mission of the Task Force will be to alert the UN Secretary-General on matters related to emerging crises and any gaps or weaknesses in the world health system.
Researchers from the Institut Pasteur, CNRS and Vaccine Research Institute (ANRS/Inserm) recently shown that some effective antibodies recognize cells infected by the human immunodeficiency virus (HIV) and trigger their destruction by the immune system.
This discovery sheds new light on the mechanism of action of these specific antibodies, which are currently undergoing clinical trials. These findings are published in Nature Communications on March 3rd , 2016.
Using innovative technology, scientists from the Institut Pasteur and Inserm filmed in vivo the process by which an AIDS vaccine candidate, developed by the French Vaccine Research Institute and the ANRS, triggers the immune response. This previously unseen footage clearly shows how the vaccine recruits the immune cells needed to destroy infected cells.
These results, published in the journal Nature Medicine on December 21, 2015, shed new light on the mode of action and potential of this vaccine.